ARK 每周股评 – 3/6/2022

我们每周都会与投资者分享我们策略中一周内一天内升值或下跌超过15%的股票的周评。我们希望您觉得这篇评论有用。

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Evogene Ltd. (EVGN)

+15%

Shares of Evogene rose 15% on Monday, participating in a broad market rally––disproportionately so perhaps because of its small market capitalization. Evogene is a diversified Israeli biotech company with subsidiaries focused on agriculture, cannabis, and pharmaceutical development. 注: Evogene公司的股票周一上涨了15%，参与了广泛的市场反弹--也许是因为其市值小，所以不成比例地上涨。Evogene是一家多元化的以色列生物技术公司，其子公司专注于农业、大麻和医药开发。

Elbit Systems Ltd. (ESLT)

+15%	Shares of Elbit, a leading Israeli drone company, traded up 15% on Monday following Russia's invasion of Ukraine.  注: 在俄罗斯入侵乌克兰之后，以色列领先的无人机公司Elbit的股价在周一上涨了15%。

Tinkoff (TCS:LI)

-73%

Shares of Tinkoff traded down 73% on Monday, 48% on Tuesday, and 37% on Wednesday as Russia intensified its invasion of Ukraine and Western countries began to isolate Russia with financial and other economic sanctions. Tinkoff reported fourth quarter earnings on Friday and provided an update on its operations in Russia. Currently, Tinkoff is in a solid financial position based on its liquidity and capital. It still is connected to SWIFT and is not on the Specially Designated Nationals and Blocked Persons list (SDN). The London Stock Exchange has suspended trading of TCS. LI, Tinkoff's parent company. Based on its consumer-centric focus and its market share gains during past crises, we have confidence in Tinkoff’s management’s ability to overcome the impact of the current tragedy with time. That said, what happens to Russia's economy in the short term is beyond Tinkoff's control. 注: 由于俄罗斯加强了对乌克兰的入侵，西方国家开始用金融和其他经济制裁来孤立俄罗斯，天科夫的股票周一下跌73%，周二下跌48%，周三下跌37%。Tinkoff周五公布了第四季度财报，并提供了关于其在俄罗斯运营的最新情况。目前，基于其流动性和资本，廷科夫处于稳固的财务状况。它仍然与SWIFT系统相连，并且不在特别指定国民和受阻人员名单上（SDN）。伦敦证券交易所已经暂停了TCS的交易。LI，Tinkoff的母公司。基于其以消费者为中心的关注点以及在过去的危机中获得的市场份额，我们对天科夫的管理层有信心，他们有能力随着时间的推移克服当前悲剧的影响。也就是说，俄罗斯的经济在短期内发生什么是丁克夫无法控制的。

Intellia Therapeutics (NTLA)

-19%

Shares of Intellia traded down 19% on Tuesday, pulling back from its 27% gain after the company reported earnings on Monday. The company released data demonstrating the efficacy of its gene editing therapy for the treatment of transthyretin-related hereditary amyloidosis (hATTR), including an average 93% reduction in the concentration of the mutant protein among the trial subjects––a significant improvement over existing hATTR therapies. Intellia is a next-generation biopharmaceutical company developing in- and ex-vivo gene therapies for the treatment of rare genetic diseases. 注: Intellia公司的股票周二下跌了19%，从该公司周一公布收益后27%的涨幅中拉了回来。该公司发布的数据显示，其基因编辑疗法对治疗转甲状腺素相关的遗传性淀粉样变性（hATTR）具有疗效，包括试验对象中突变蛋白的浓度平均降低93%--与现有的hATTR疗法相比，这是一项重大改进。Intellia是一家开发体内和体外基因疗法以治疗罕见遗传病的下一代生物制药公司。

Kaspi.KZ JSC (KSPI)

-31%

Shares of Kaspi traded down 31% on Wednesday as the effects of Russia's attack on Ukraine rippled through Eastern Europe and Central Asia. Kaspi released fourth quarter earnings on Monday and confirmed that it has no meaningful exposure to sanctioned Russian financial Institutions. 注: 由于俄罗斯对乌克兰的攻击影响波及东欧和中亚，Kaspi的股价在周三下跌了31%。Kaspi周一发布了第四季度财报，并确认其对被制裁的俄罗斯金融机构没有任何有意义的风险。

Veeva Systems (VEEV)

-16%

Shares of Veeva Systems, a leading provider of enterprise cloud solutions for life science companies, traded down roughly 16% on Thursday following lower than expected revenue guidance during the company’s fourth quarter earnings call. ARK remains confident that Veeva’s emerging products, including ePro and eConsent, will catalyze growth in the coming quarters and years. 注: 为生命科学公司提供企业云解决方案的领先供应商Veeva Systems的股价周四下跌了约16%，因为该公司在第四季度财报电话会议上的收入指导低于预期。ARK仍然相信Veeva的新兴产品，包括ePro和eConsent，将在未来几个季度和几年催化增长。

TuSimple Holdings Inc. (TSP)

-21%

Shares of TuSimple traded down 21% on Thursday following the announcement that CTO Xiaodi Hou, one of the two founders of this autonomous trucking company, will replace CEO Cheng Lu. We have confidence in Xiaodi’s ability to execute on TuSimple’s autonomous strategy. 注: 在宣布首席技术官侯晓迪（这家自主卡车公司的两位创始人之一）将取代首席执行官程路之后，图森未来的股价在周四下跌了21%。我们对Xiaodi执行图森未来自主战略的能力充满信心。

Recursion Pharmaceuticals Inc. (RXRX)

-16%

Shares of Recursion Pharmaceuticals traded down 16% on Friday after the company announced delays in its trial investigating a treatment for infantile GM2 gangliosidosis. We view the delay as prudent and maintain our positive thesis on the company. Recursion Pharmaceuticals is a clinical-stage drug discovery and development company taking advantage of the convergences between and among biology, chemistry, automation, machine learning, and engineering. 注: 周五Recursion Pharmaceuticals公司的股票下跌了16%，因为该公司宣布推迟调查治疗婴儿GM2神经节苷脂病的试验。我们认为延迟是审慎的，并维持我们对该公司的正面看法。Recursion Pharmaceuticals是一家处于临床阶段的药物发现和开发公司，利用生物学、化学、自动化、机器学习和工程之间的融合优势。

Snowflake Inc. (SNOW)

-15%

Shares of Snowflake fell 15% on Thursday after the company reported fourth quarter earnings on Wednesday afternoon. After reporting better than expected product revenue growth of 102% on a year-over-year basis, 178% net revenue retention, and 139% growth in the number customers contributing over $1 million in product revenue, management offered guidance for the first quarter and full year that revenues would increase 79% to 81% and 66% year-over-year, respectively, a meaningful deceleration from 106% revenue growth in 2021. If it maintains its high net retention rates and strong execution in enterprise upsell, we believe that Snowflake will remain a core software vendor as more enterprises transition to cloud-native formats. Snowflake provides cloud-based data platforms that enable customers to store, manipulate, and build on data no matter where it resides. 注: Snowflake的股票在周四下跌了15%，此前该公司在周三下午公布了第四季度收益。在报告了好于预期的产品收入同比增长102%，净收入保留率178%，以及贡献超过100万美元产品收入的客户数量增长139%之后，管理层提供了第一季度和全年的指导，收入将分别同比增长79%至81%和66%，比2021年106%的收入增长有意义地减速。如果它能保持其高净留存率和企业追加销售的强大执行力，我们相信，随着越来越多的企业过渡到云原生格式，Snowflake将继续成为核心软件供应商。Snowflake提供基于云的数据平台，使客户能够存储，操作和建立在数据上，无论它位于何处。